Merck Units To Pay $44M In Rebif Whistleblower Suit
Merck KGaA affiliates have agreed to pay $44.3 million to resolve a whistleblower's allegations that they bought off health care providers to promote or prescribe the multiple sclerosis drug Rebif, resulting...To view the full article, register now.
Already a subscriber? Click here to view full article